Dr. Kaufmann's appointment, with her vast experience in neurological and rare diseases, is anticipated to benefit Vigil as it progresses the development of its drugs iluzanebart and VG-3927. Her expertise in both domestic and global drug development is considered a valuable asset for the company.
ヴィジル・ニューロサイエンスに関するコメント
Support
Very low volume, but I like the setup. I'm going to throw a little something on this one and keep a close eye on it.
コラムIPO Buzz | 2022 IPO market kicks off with 3 biotechs set to trade on Friday
まだコメントはありません